Management

Damian Marron

Interim CEO since 2025, born 1962. Number of shares: 63 054

Damian Marron has extensive experience as a Board Member and CEO within the life science industry, with a successful track record of leadership and value creation in public and private biotechnology companies. Marron has held positions as CEO and Executive Vice President in several biotech companies. He is currently Chairman of the Board of Targovax ASA, Imophoron Ltd, Indegra Therapeutics Ltd and Board Member of Resolys Bio Inc. and Onya Therapeutics Ltd, and Head of Biopharma at Treehill Partners.
Marron holds a BSc degree in Pharmacology from the University of Liverpool.
Independent in relation to the Company and its management and the Companys major shareholders

David Liberg

CSO employed since 2015, born 1969. Holdings: 69 087 shares and 475 000 options

David Liberg graduated with a PhD in 2001 and has over twentyfive years of research experience within immunology and tumour biology. Liberg has worked within the pharmaceutical industry for the last eighteen years, with responsibility for early research projects and activities in tumour immunology. He has extensive experience of pre-clinical phase cancer projects. His most recent position was at Active Biotech AB, where he worked as Project Manager Drug Development as well as Head of Cell Biology and Biochemistry. Liberg has also carried out research at Imperial College in the UK and at Lund University.

Patrik Renblad

CFO employed since 2023, born 1970. Holdings: 141 405 shares and 350 000 options

Patrik Renblad holds a MSc in Business Administration and Economics from Lund University. He has more than 20 years of experience from the Life Science industry. With a strong financial background and focus, he has served in various roles across the pharmaceutical value chain and across geographies for AstraZeneca, LEO Pharma and SynAct Pharma. Prior to joining Cantargia, Renblad led SynAct Pharmas listing on Nasdaq Stockholm in 2022 as CFO. Before that, he served 10 years at LEO Pharma, amongst his roles were head of Research & Development Finance unit and local CFO for the Chinese affiliate in Shanghai.

Ton Berkien

CBO employed since 2024, born 1968. Holdings: 53 423 shares and 170 000 options

Ton Berkien holds a BA degree in economics/business information from Saxion University of Applied Sciences in the Netherlands, as well as an LSid from SIMI and from PwC/Harvard Business School/IMD. He has more than 20 years of experience in the Life Science Industry. Berkien has previously held senior business development positions at Amgen, Nuevolution, Takeda and Nycomed. Before that he held positions at Ferring Pharmaceuticals, PwC, KPMG and Gilde Investment Management. Further, he is Chairman of the Board in Gedea Biotech AB and board member in Adjutec Pharma A/S.

Morten Lind Jensen

CMO employed since 2025, born 1979. Holdings: 0 shares and 0 options

Morten Lind Jensen is an MD and holds PhD, from University of Copenhagen, Denmark and a Diploma in Pharmaceutical Medicine from the Royal Colleges of Physicians of the United Kingdom. He has more than 10 years of experience from the Life Science industry. Prior to Cantargia, Lind Jensen held the position as Chief Medical Officer at UNION therapeutics A/S, where he worked in clinical development. He has served in various roles at Novo Nordisk such as medical specialist, Project Manager and Line Manager. His experience covers the therapeutic areas of Hidradenitis Suppurativa, Atopic Dermatitis, Psoriasis, Ulcerative Colitis and viral airway infections. Lind Jensen is currently a board member of HEDIA A/S, and BIBAWO Medical A/S.

Lars Thorsson

VP Clinical Development employed since 2015, born 1961. Holdings: 168 686 shares and 435 000 options

Lars Thorsson graduated with a PhD in clinical pharmacology in 1998 and has extensive experience from the pharmaceutical industry, including leading roles in clinical studies and project management in a large number of development phases at AstraZeneca and Novo Nordisk A/S. Thorsson has been responsible for evaluation and documentation of new substances and has the experience of regulatory activities and interactions with health authorities.

Nedjad Losic

VP Biometrics employed since 2021, born 1969. Holdings: 60 000 shares and 330 000 options

Nedjad Losic holds an MSc in Mathematics and a diploma in Management of Medical Product Innovation (SIMI). Losic has over 25 years of experience in providing biostatistics expertise in clinical drug development, mostly in antibody development and oncology. Losic has been directly involved in the planning and obtaining market approvals for several biological drugs at Genmab and Y-mAbs Therapeutics. He has previously held managerial positions and worked for Ferring, Spadille, Genmab and Y-mAbs.